Slow released anticancer injection
A technology of slow-release injections and slow-release implants, which is applied to antineoplastic drugs, medical preparations containing active ingredients, organic active ingredients, etc., and can solve problems such as poor curative effect, difficult operation, and many complications
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0111] Put 80mg of polyphenylpropanine (p-carboxyphenylpropane (p-CPP): sebacic acid (SA) 20:80) copolymer into the container, add 100ml of dichloromethane, dissolve and mix well, add 10mg Actinomycin D and 10 mg formustine were shaken again and spray-dried to prepare injection microspheres containing 10% actinomycin D and 10% formustine. Then the microspheres were suspended in physiological saline containing 15% mannitol to prepare the corresponding suspension type sustained-release injection with a viscosity of 220cp-460cp (at 20°C-30°C). The release time of the sustained-release injection in physiological saline in vitro is 10-15 days, and the release time under the skin of mice is about 20-30 days.
Embodiment 2
[0113] The method steps for processing into a sustained-release injection are the same as in Example 1, but the difference is that the anti-cancer active ingredients and their weight percentages are:
[0114] (1) 2-40% of formustine or bendamustine and 2-40% of melphalan, 4H-peroxycyclophosphamide, vinorelbine, tamoxifen, methotrexate, doxorubicin , Epirubicin or Actinomycin D;
[0115] (2) 2-40% of tamustine or carmustine and 2-40% of melphalan, 4H-peroxycyclophosphamide, vinorelbine, tamoxifen, methotrexate, adriamycin, Combination of epirubicin or actinomycin D;
[0116] (3) 2-40% of Nimustine or Lomustine and 2-40% of Melphalan, 4H-Peroxycyclophosphamide, Vinorelbine, Tamoxifen, Methotrexate, Adriamycin, Combination of Epirubicin or Actinomycin D; or
[0117] (4) 2-40% of semustine or ramustine and 2-40% of melphalan, 4H-peroxycyclophosphamide, vinorelbine, tamoxifen, methotrexate, adriamycin, Combination of epirubicin or actinomycin D.
[0118] The sustained-release excipient...
Embodiment 3
[0120] Put 70mg of polylactic acid (PLGA, 75:25) with a peak molecular weight of 65000 into a container, add 100ml of dichloromethane, dissolve and mix well, add 15mg of carmustine and 15mg of melphalan, shake well and vacuum Dry to remove organic solvents. The dried drug-containing solid composition was freeze-pulverized into a micropowder containing 15% carmustine and 15% melphalan, and then suspended in physiological saline containing 1.5% sodium carboxymethyl cellulose to prepare the corresponding Suspension type sustained-release injection, viscosity of 300cp-400cp (at 20℃-30℃). The release time of the sustained-release injection in physiological saline in vitro is 10-15 days, and the release time under the skin of mice is about 20-30 days.
PUM
Property | Measurement | Unit |
---|---|---|
glass transition temperature | aaaaa | aaaaa |
melting point | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com